An observational study in Cognitive Impairment, Dementia and Psychiatric Disorder, sponsored by Istituto Auxologico Italiano. Recruiting at 1 site in Italy. Open to participants aged 20 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-17.
Sponsored by Istituto Auxologico Italiano · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 175 studies in Cognitive Dysfunction with a site in Italy — 74 open to participants now, 87 under way, 6 of them phase 3. Cognitive Dysfunction · Italy.
Among the 175 studies in Cognitive Dysfunction with a site in Italy, this one is the 20th largest by planned enrollment of the 64 observational ones that give a count, is one of 16 that started in 2021, is one of 64 observational ones, reaches primary completion later than 46 of the 86 other live ones, and was the 71st registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →74 of the 175 studies in Cognitive Dysfunction with a site in Italy are open now. Recruiting first, the newest first:
Istituto per la Ricerca e l'Innovazione Biomedica · Sites in Italy
Ages 18–85 · Healthy volunteers
IRCCS Centro San Giovanni di Dio Fatebenefratelli · Sites in Italy
Ages 18+
Alfonso Magliacano · Sites in Italy
Ages 18–75 · Healthy volunteers
University of Milano Bicocca · Sites in Italy
Ages 65+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 55–80 · Healthy volunteers
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 20 Years to 100 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
175 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 8 · Phase 4 1
First in 2007; this study’s year is marked. 16 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 150 across 1,000 observational studies indexed under Cognitive Dysfunction.
Median enrollment 80 across the 111 interventional studies, 182 across the 64 observational. Of the 59 that completed or were terminated, 7 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 175 have an industry lead sponsor. The 10 most frequent:
Istituto Auxologico Italiano is the lead sponsor of 204 studies on the registry; 70 are open to participants now.
Istituto Auxologico Italiano has 6 studies filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
23 of the studies in Cognitive Dysfunction with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT06657274IRCCS Centro San Giovanni di Dio FatebenefratelliEARLY-COGN^3 - Smart Digital Solutions for EARLY Treatment of COGnitive Disability: a Neuropsychological, Neurophysiological and Neurobiological Perspective in Chronic Neurological Diseases - PNRR-MCNT2-2023-12377069 | 2026-11-30 |
| NCT07286448Giovanna ZamboniPersonalized Digital Training for COGnitive FITness in Mild Cognitive Impairment | 2026-11-30 |
| NCT06701630Casa di Cura IGEAItalian Adaptation and Validation of Functional and Behavioural Scales for Subjective Cognitive Decline, Mild Cognitive Impairment and Mild Dementia. | 2026-11-30 |
| NCT07616050Marta MondelliniEvaluation of the Impact of Virtual Park on Training Motivation in Adult Patients | 2026-12 |
Add all 23 to your calendar (.ics) → With an account.
Among the 175 studies in Cognitive Dysfunction with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project is aimed at advancing neuropsychological diagnostics, enriching and modernizing the panorama of both clinical and forensic psychometric testing. The rapid socio-demographic changes, the developments of neuropsychological semiotics and nosography, as well as the growing applicative specialization of neuropsychological assessment make it necessary to introduce further tools to satisfy the diagnostic requests in clinical contexts and more recently in the forensic field (i.e., tests to be administered remotely; bedside screeners; domain-specific in-depth tests; tools for assessing testamentary capacity).
Specifically, the present study aims to: a) develop, calibrate and evaluate the psychometric properties of I and II level clinical and/or forensic neuropsychological tests evaluating instrumental and non-instrumental functions in a sample of neurologically healthy individuals representative of the Italian population ; b) evaluate the cross-sectional and longitudinal clinical usability of the aforementioned tests in clinical samples (patients with neurological and neuropsychiatric pathologies of different etiology).
Individuals with brain disorders and normotypical.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Clinical populations:
Healthy controls:
Patients with brain disorders
Behavioral: Neuropsychological instruments
Neurologically Healthy Controls
Behavioral: Neuropsychological instruments
Cognitive and behavioral tests and questionnaires
Change from baseline in Brief Assessment of Social Skills-Dementia (BASS-D)
A screening test of social cognition in neurodegeneration
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Picture Interpretation Test (PIT)
A test of executive functions
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Verbal Reasoning Test (VRT-A) - Absurdity sub-test
A test of verbal reasoning
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Brief Executive Language Screen (BELS)
A language test
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Bamberg Dementia Screening Test (BDST)
A test of global cognitive efficiency
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Testament Definition Scale (TDS)
A scale to assess testament representation
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Testamentary Capacity Assessment Tool (TCAT)
A test to assess cognitive functions (i.e., memory, executive functions, social cognition, and numerical abilities) at the base of testamentary capacity
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Telephone Interview for Cognitive Status (TICS)
A telephone-based screening test of global cognitive efficiency
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Telephone-based Mini-Mental State Examination (I-TEL-MMSE)
A telephone-based screening test of global cognitive efficiency
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Telephone-based Global Examination of Mental State (tele-GEMS)
A telephone-based screening test of global cognitive efficiency
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Telephone-based Amyotrophic Lateral Sclerosis Cognitive Behavioural Screen (ALS-CBS™-PhV
A telephone-based screening test for cognitive functions in ALS
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Telephone-based Frontal Assessment Battery (t-FAB)
A telephone-based screening test of executive functions
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Development of the Bizzare Pictures Test (BPT)
A new visual test to assess reasoning abilities
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Change from baseline in Development Telephone Language Screener (TLS)
A new telephone-based test to asses linguistic functions
Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders
Started Nov 2021 (actual). Primary completion is estimated for Dec 2026, 61 months after the start.
Of 506 non-industry observational studies under Cognitive Dysfunction, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's planned 61 months is above that.
Counting every sponsor, half of 545 studies reached it within 48 months; a quarter within 21 and three quarters within 118.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istituto Auxologico Italiano →